Escherichia coli bacteriophage targeting escherichia coli lipopolysaccharide core polysaccharide and application of escherichia coli bacteriophage

Through the E. coli phage GEP101 targeting E. coli lipopolysaccharide core polysaccharide, the transmission and infection problems of enterohemorrhagic E. coli O157:H7 were solved, effective inhibition and prevention of a variety of E. coli, and safe and efficient Solution to avoid the problem of antibiotic use.

CN119020302AActive Publication Date: 2024-11-26HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202411139545.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-26
Estimated Expiration
2044-08-20

AI Technical Summary

Technical Problem

The prior art is difficult to effectively control and prevent the transmission and infection of enterohemorrhagic E. coli O157:H7, especially in the context of enhanced antibiotic resistance, and lacks safe, efficient and environmentally friendly alternative therapies.

Method used

A E. coli phage GEP101 targeting E. coli lipopolysaccharide core polysaccharide was developed, with a broad lysis spectrum, which can effectively inhibit various serotypes of E. coli including enterohemorrhagic E. coli O157:H7 and does not contain toxicity. Force genes, drug resistance genes and lysogenic genes have good environmental stability and safety.

Benefits of technology

The phage can effectively inhibit E. coli, prevent its infection, and inhibit its proliferation in food, providing a safe and efficient way to prevent and treat E. coli infection, avoiding the residual problems of traditional chemical disinfectants and antibiotics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020302A_ABST
    Figure CN119020302A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of microorganisms, and particularly relates to an escherichia coli bacteriophage targeting escherichia coli lipopolysaccharide core polysaccharide and application of the escherichia coli bacteriophage. The preservation number of the escherichia coli bacteriophage GEP101 disclosed by the invention is CCTCC (China Center for Type Culture Collection) NO: M 20241332. The Escherichia coli phage GEP101 disclosed by the invention can be used for cracking various serotypes of Escherichia coli including enterohemorrhagic Escherichia coli O157: H7, has good environmental stability, does not contain any virulence gene, drug-resistant gene and lysogenic gene, has good safety, and can be used for effectively inhibiting Escherichia coli and preventing infection of Escherichia coli.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of microorganisms, and in particular relates to an Escherichia coli phage targeting Escherichia coli lipopolysaccharide core polysaccharide and an application thereof. Background Art

[0002] Escherichia coli is a Gram-negative bacterium that is widely distributed in the intestines of humans and animals, in the soil surface, and in water bodies. It can also be spread to the environment, feed, water sources, and food through animal carrying or excretion. At present, Escherichia coli is divided into different types according to its pathogenic mechanism and clinical symptoms: enteropathogenic Escherichia coli, enterohemorrhagic Escherichia coli, enterotoxigenic Escherichia coli, enteroinvasive Escherichia coli, and diffusely adherent Escherichia coli. Among them, enterohemorrhagic Escherichia coli O157:H7 is one of the zoonotic foodborne pathogens that seriously endangers public health safety. According to statistics, enterohemorrhagic Escherichia coli O157:H7 mostly infects the human body through media such as milk or milk products, beef, vegetables, and water, causing diseases such as diarrhea and hemorrhagic colitis. In severe cases, it can even lead to life-threatening hemolytic uremic syndrome. Therefore, it is particularly important to control and prevent enterohemorrhagic Escherichia coli O157:H7 contamination.

[0003] The discovery and use of antibiotics has reduced the number of diseases caused by foodborne pathogenic bacteria, but due to the extensive use of antibiotics and irrational use, more and more bacteria have developed drug resistance or even multi-drug resistance, posing a huge threat to global public health. The development cycle of new antibiotics is long, and the speed of new antibiotic development is difficult to cope with the phenomenon of rapid bacterial resistance. Therefore, there is an urgent need for a safe, efficient and environmentally friendly antibiotic alternative therapy to prevent and treat pathogenic E. coli infections.

[0004] Bacteriophages are viruses that specifically infect and kill host bacteria. They are the most abundant organisms in nature and have advantages over traditional antibiotics in terms of target specificity, low resistance, and biosafety. In the face of serious drug resistance and multidrug resistance, E. coli, as an important zoonotic and foodborne pathogen, urgently needs to adopt more efficient methods to prevent and control E. coli infections. Summary of the invention

[0005] The object of the present invention is to provide an Escherichia coli phage targeting the Escherichia coli lipopolysaccharide core polysaccharide and its application. The Escherichia coli phage of the present invention has a wide lysis spectrum, can lyse Escherichia coli of different serotypes, effectively inhibit Escherichia coli and prevent Escherichia coli infection.

[0006] The invention provides an Escherichia coli phage (Escherichia coliphage) GEP101. The deposit number of the Escherichia coli phage GEP101 is CCTCC NO: M 20241332.

[0007] The present invention also provides the use of the Escherichia coli phage GEP101 described in the above technical solution in the preparation of a preparation for inhibiting and / or lysing Escherichia coli.

[0008] Preferably, the formulation comprises a formulation targeting the Escherichia coli lipopolysaccharide core polysaccharide.

[0009] Preferably, the Escherichia coli includes one or more of serotype Escherichia coli O157, serotype Escherichia coli O66, serotype Escherichia coli O77 / O17, serotype Escherichia coli K88, serotype Escherichia coli O131, serotype Escherichia coli O177 and serotype Escherichia coli O159.

[0010] Preferably, the multiplicity of infection of the Escherichia coli phage GEP101 is 0.01-10.

[0011] Preferably, the preparation comprises a food antibacterial agent.

[0012] Preferably, the food comprises food of animal origin.

[0013] Preferably, the preparation comprises a drug for preventing and / or treating a disease caused by Escherichia coli infection.

[0014] The present invention also provides a preparation for inhibiting and / or lysing Escherichia coli, comprising the Escherichia coli phage GEP101 described in the above technical solution and auxiliary materials.

[0015] Preferably, the content of Escherichia coli phage GEP101 added to the preparation is 10 6 PFU / mL~10 8 PFU / mL.

[0016] Beneficial effects:

[0017] The present invention provides an Escherichia coli phage GEP101, and the deposit number of the Escherichia coli phage GEP101 is CCTCC NO: M 20241332. The Escherichia coli phage GEP101 of the present invention has a wide lysis spectrum, can lyse Escherichia coli of various serotypes including enterohemorrhagic Escherichia coli O157:H7, has good environmental stability, does not contain any virulence gene, drug resistance gene and lysogeny gene, has good safety, effectively inhibits Escherichia coli and prevents infection of Escherichia coli, and compared with traditional chemical disinfectants and antibiotics, has the characteristics of high specificity, safety and no residue.

[0018] Biological deposit information

[0019] Escherichia coliphage GEP101 was deposited in the China Center for Type Culture Collection on June 21, 2024. The deposit address is: Wuhan University, No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province, and the deposit number is: CCTCC NO: M 20241332. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below. Obviously,

[0021] Figure 1 This is a diagram showing the plaque morphology of the purified Escherichia coli phage GEP101 in Example 1;

[0022] Figure 2 The transmission electron microscope morphology of the Escherichia coli phage GEP101 in Example 1 is shown;

[0023] Figure 3 This is a diagram showing the receptor identification results of Escherichia coli phage GEP101 in Example 3;

[0024] Figure 4 This is a diagram showing the optimal multiplicity of infection of Escherichia coli phage GEP101 in Example 4;

[0025] Figure 5 is the one-step growth curve of Escherichia coli phage GEP101 in Example 5;

[0026] Figure 6 This is a graph showing the pH stability results of the Escherichia coli phage GEP101 in Example 6;

[0027] Figure 7 This is a graph showing the thermal stability results of Escherichia coli phage GEP101 in Example 7;

[0028] Figure 8 is the lysis curve of Escherichia coli phage GEP101 at different MOIs in Example 8;

[0029] Fig. 9 is the genome annotation map of Escherichia coli phage GEP101 in Example 9;

[0030] Fig.10 This is a graph showing the inhibitory effect of Escherichia coli phage GEP101 in Example 10 on enterohemorrhagic Escherichia coli O157:H7 in milk. DETAILED DESCRIPTION

[0031] The invention provides an Escherichia coli phage (Escherichia coliphage) GEP101. The deposit number of the Escherichia coli phage GEP101 is CCTCC NO: M 20241332.

[0032] The Escherichia coli phage GEP101 of the present invention is isolated from pig farm sewage using enterohemorrhagic Escherichia coli O157:H7 (ATCC 35150) as a host bacterium. The Escherichia coli phage GEP101 is observed by transmission electron microscopy, and it is found that the head of the Escherichia coli phage GEP101 is a regular polyhedron with a head diameter of 71±2nm, a retractable tail, and a tail length of 121±2nm, and belongs to the myocaudal phage of the order Caudovirales and the family Myocaudalphaga.

[0033] The Escherichia coli phage GEP101 of the present invention can form transparent plaques on the LB double-layer plate; after being exposed to a pH value of 3-10 for 1 hour, the activity remains stable; the activity is stable under a temperature condition of 4°C-50°C, and the phage titer is 10 8 PFU / mL, still maintains good stability at 60-70℃, and the phage titer is 10 7 PFU / mL. The genome size of the Escherichia coli phage GEP101 described in the present invention is 88,372bp, and the genome of the Escherichia coli phage GEP101 does not contain virulence genes, drug-resistant genes and lysogenic genes. Through experiments, it was found that the Escherichia coli phage GEP101 described in the present invention has a wide Escherichia coli lysis spectrum and can lyse various serotypes of Escherichia coli including enterohemorrhagic Escherichia coli O157:H7. Therefore, combined with the above-mentioned technical features, it can be seen that the Escherichia coli phage GEP101 described in the present invention has good environmental stability, does not contain any virulence genes, drug-resistant genes and lysogenic genes, has good safety, and effectively inhibits Escherichia coli and prevents Escherichia coli infection.

[0034] Based on the above advantages, the present invention also provides the use of the Escherichia coli phage GEP101 described in the above technical solution in the preparation of a preparation for inhibiting and / or lysing Escherichia coli. The preparation of the present invention preferably includes a preparation targeting the Escherichia coli lipopolysaccharide (LPS) core polysaccharide, that is, the Escherichia coli phage GEP101 uses the lipopolysaccharide core polysaccharide in Escherichia coli as a receptor to lyse Escherichia coli and exert an inhibitory effect on Escherichia coli. The Escherichia coli described in the present invention preferably includes: one or more of serotype Escherichia coli O157, serotype Escherichia coli O66, serotype Escherichia coli O77 / O17, serotype Escherichia coli K88, serotype Escherichia coli O131, serotype Escherichia coli O177 and serotype Escherichia coli O159, and is further preferably serotype Escherichia coli O157, serotype Escherichia coli O66, serotype Escherichia coli O77 / O17, serotype Escherichia coli K88, serotype Escherichia coli O131, serotype Escherichia coli O177 and serotype Escherichia coli O159; the O157 serotype Escherichia coli is preferably enterohemorrhagic Escherichia coli O157:H7.

[0035] The multiplicity of infection of the Escherichia coli phage GEP101 of the present invention is preferably 0.01-10, more preferably 0.1-1, and more preferably 1, that is, the optimal multiplicity of infection of the Escherichia coli phage GEP101 is 1.

[0036] The preparation of the present invention preferably includes a food antibacterial agent; the food antibacterial agent preferably inhibits or kills Escherichia coli on the surface of food or in food; the food preferably includes animal-derived food, further preferably includes but is not limited to dairy products, and more preferably milk, that is, the Escherichia coli phage GEP101 can inhibit the proliferation of Escherichia coli in food, prevent Escherichia coli from infecting food, and especially inhibit or prevent enterohemorrhagic Escherichia coli O157:H7 from contaminating food.

[0037] The preparation of the present invention preferably includes drugs for preventing and / or treating diseases caused by Escherichia coli infection, more preferably drugs for preventing and treating diseases caused by Escherichia coli infection, such as drugs for preventing and treating diarrhea or hemorrhagic colitis.

[0038] The present invention also provides a preparation for inhibiting and / or lysing Escherichia coli, comprising the Escherichia coli phage GEP101 and auxiliary materials as described in the above technical solution. The auxiliary materials of the present invention preferably include a buffer reagent for Escherichia coli phage GEP101, and further preferably but not limited to SM Buffer. The content of Escherichia coli phage GEP101 in the preparation of the present invention is preferably 10 6 PFU / mL~10 8 PFU / mL, more preferably 10 7The preparation of the present invention preferably includes a food antibacterial agent, or a drug for preventing and / or treating diseases caused by Escherichia coli infection; the food is preferably animal-derived food, and further preferably includes but is not limited to dairy products.

[0039] In order to further illustrate the present invention, the technical solution provided by the present invention is described in detail below in conjunction with the accompanying drawings and embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0040] Example 1

[0041] Isolation and purification of Escherichia coli phage GEP101 targeting Escherichia coli LPS core polysaccharide

[0042] (1) Isolation and purification of bacteriophage GEP101

[0043] Take 15mL of pig farm sewage sample and centrifuge it at 5000×g for 15min to remove impurities. Filter the supernatant with a 0.22μm filter for later use. Take 2mL of Escherichia coli ATCC 35150 suspension in the logarithmic growth period and add it to a 15mL sterile centrifuge tube containing 3mL of LB liquid culture medium, and add 2mL of filtered sewage to mix evenly. Place it in a shaker and culture it at 37℃ for 6-8h to allow the phage to proliferate. Centrifuge the cultured mixture at 12000×g for 5min and filter the supernatant with a 0.22μm filter. The filtered supernatant was diluted in a 10-fold gradient, 100 μL of the dilutions of different gradients was mixed with 100 μL of Escherichia coli ATCC35150 and added to 5 mL of melted LB semi-solid medium (containing 0.7 wt.% agar), and then covered on LB solid agar (containing 1.5 wt.% agar) after mixing. After cooling, it was placed in a 37°C incubator for static culture.

[0044] Pick out the transparent single plaque and resuspend it in SM buffer to obtain the phage extract. Filter the extract through a 0.22μm filter, then use SM buffer to perform a 10-fold gradient dilution, and use the double-layer plate method to obtain a single phage plaque. Repeat the purification 3-4 times to obtain a single phage plaque with consistent morphology and size.

[0045] (2) Proliferation and titer determination of bacteriophage GEP101

[0046] The purified phage single plaque was resuspended in SM buffer to obtain phage extract. 100 μL of phage extract was added to LB medium containing 5 mL of Escherichia coli ATCC 35150 in the logarithmic growth phase, and incubated at 37°C, 160 rpm for 4 hours. The lysate was then centrifuged at 8000 × g for 5 minutes, and the supernatant was filtered through a 0.22 μm filter to remove the remaining bacteria to obtain the proliferated phage extract, which was diluted 10 times in a gradient using SM buffer, and stored at 4°C after testing its titer.

[0047] The phage GEP101 formed uniform, regular circular plaques with a diameter of about 1 mm on the double-layer plate (such as Figure 1 ), the phage titer was 5×10 8 PFU / mL.

[0048] (3) Transmission electron microscopy observation of phage GEP101 morphology

[0049] Using the phosphotungstic acid negative staining method, take 10 μL of the purified and concentrated 10 9 PFU / mL phage extract was added dropwise onto the copper mesh. After standing for 10 min, the residual suspension on the surface was removed with filter paper. 10 μL of 2% phosphotungstic acid (PTA, 2% w / v) dye was added for negative staining for 2 min. The excess dye was removed and the mesh was dried naturally. The prepared copper mesh was observed under a transmission electron microscope.

[0050] The results are as follows Figure 2 Under transmission electron microscopy, the phage head is a polyhedron with a retractable tail. The head diameter is about 72±2nm and the tail length is about 121±2nm. GEP101 belongs to the order Caudovirales, the family Myoviridae, and is named Escherichia coli phage GEP101. It has been deposited in the China Center for Type Culture Collection with the deposit number CCTCC NO: M 20241332.

[0051] Example 2

[0052] Detection of lysis spectrum of bacteriophage GEP101

[0053] The bacteria used to determine the lysis spectrum of the phage GEP101 were all from the laboratory. The spotting method was used to determine the lysis spectrum of the phage. Each bacterial suspension was added to LB liquid culture medium and cultured overnight at 37°C. 100 μL of the overnight bacterial suspension was added to 5 mL of melted LB semi-solid culture medium. After mixing, pour into a double-layer plate and wait for it to cool and solidify. 10 μL of 10 8The PFU / mL phage GEP101 proliferation solution was spotted onto a double-layer plate, naturally dried until it stopped flowing, and then inverted in a 37°C constant temperature incubator for 6-12 hours to observe the lysis of the test strains by the phage. The results are shown in Table 1. Bacteriophage GEP101 can lyse 15 different strains of Escherichia coli.

[0054] Table 1. Phage GDP101 lysis spectrum

[0055]

[0056]

[0057] Example 3: Phage receptor identification

[0058] There are many ways to identify phage host receptors, such as sequencing mutants that are resistant to phages and comparing gene mutation sites, screening transposon random mutant libraries, and constructing a knockout strain library of commonly used phage receptor genes. In this study, the receptors were identified by constructing gene knockout strains of commonly used phage receptors. The λ-Red homologous recombination technology was used to construct the lipopolysaccharide-O antigen gene knockout strain (rfaL gene) and the lipopolysaccharide core polysaccharide gene knockout strain (rfaC gene) of enterohemorrhagic Escherichia coli ATCC 35150.

[0059] According to the whole genome sequence of ATCC 35150, upstream and downstream primers of knockout genes were designed. The primers used for the construction of rfaL and rfaC knockout strains are shown in Table 2. The primers consist of two parts. The 5' end sequence is homologous to the sequences on both sides of the target gene (without underline), and the 3' end sequence is homologous to the two sides of the cat gene on pKD4 (with underline). Using the pKD4 plasmid as a template and ATCC 35150-Red-F / R with homology arms as primers, homologous fragments were amplified to replace the target gene that was pre-knocked out in the genome.

[0060] Prepare ATCC 35150 competent cells. Pick a single colony of ATCC 35150 and inoculate it into 3mL LB medium, culture it overnight at 37℃, transfer it to 100mL LB medium at 1:100, culture it at 37℃ until the logarithmic growth phase, ice bath it for 30min, transfer it into a pre-cooled 50mL centrifuge tube, centrifuge it at 4℃ 6000r / min for 10min, collect the cells, then add 45mL deionized water, gently blow it, resuspend the cells, and wash the cells once. Then centrifuge it at 4℃ 6000r / min for 10 minutes, resuspend the cells with 45mL 10% glycerol, and wash the cells twice. Add 500μL 10% glycerol to resuspend, aliquot it into 100μL / tube, and store it at -80℃ for later use. Take a tube of competent cells and add 2μL pKD46 plasmid to mix, transfer to a pre-cooled 1mm electrode cup, and electrotransform under the conditions of voltage 2.3KV, 5.5-5.9ms. Immediately after electrotransformation, add 1mL LB medium at 37℃, 180r / min, 30℃ for 2h. Then centrifuge at 6000r / min for 6 minutes, take the concentrated bacterial solution and apply it on the LB plate containing chloramphenicol, and invert and culture at 28℃. Pick a single colony for PCR identification.

[0061] Pick a single colony that has been successfully identified and put it into 3mL LB medium, culture it overnight at 28℃, and transfer it to 100mL LB medium at a ratio of 1:100. In the LB liquid medium containing chloramphenicol, add L-arabinose with a final concentration of 10mmol / L when OD600≈0.2, and culture it at 28℃, 180r / min to the logarithmic phase (OD600≈0.5) to allow the pKD46 plasmid to fully express the recombinase Exo, Beta and Gam; take out the bacterial solution and place it on ice for precooling for 30min, centrifuge it at 4℃ 6,000r / min for 10min, collect the bacteria, add 45mL precooled deionized water to wash the bacteria once, and then wash it twice with 10% glycerol, collect the bacteria, add 100μL precooled 10% glycerol, resuspend and mix, divide it into 100μL / tube, and store it at -80℃ for later use. Then take a tube of competent cells, add 5μL of the target fragment (total amount of 500ng), mix well, transfer to a pre-cooled 1mm electroporation cup, and electroporate at 2.3KV for 5.5-5.9ms. Aspirate the electroporated bacterial solution into the preheated 1mL LB medium, mix well, and culture at 180r / min, 28℃ for 2h. Centrifuge at 6,000r / min for 6min, take the concentrated bacterial solution and spread it on the LB plate containing kanamycin, and invert it in a 37℃ incubator. Use gene knockout identification primers for PCR identification, and the correct identification is the knockout strain containing the kanamycin gene fragment.

[0062] Table 2 Primers used for gene knockout

[0063]

[0064] Take the bacterial suspension of Escherichia coli ATCC 35150 lipopolysaccharide-O antigen-deficient strain and lipopolysaccharide core polysaccharide-deficient strain respectively, and take the bacterial suspension of Escherichia coli ATCC 35150 as the control, add them into LB liquid culture medium and culture them at 37°C overnight, take 100 μL of overnight bacterial liquid and add it into 5mL melted LB semi-solid culture medium, mix well and pour into double-layer plates, wait for it to cool and solidify, take 10 μL of 10-fold gradient dilution of phage GEP101 proliferation liquid and drop it on the double-layer plates, dry it naturally until it does not flow, then invert it in a 37°C constant temperature incubator and culture it for 6 to 12 hours, and observe the lysis of the test strain by the phage. The results are as follows: Figure 3 shown.

[0065] Depend on Figure 3 The results showed that phage GEP101 could normally lyse the E. coli ATCC 35150 lipopolysaccharide-O antigen-deficient strain, but could not lyse the lipopolysaccharide core polysaccharide-deficient strain. Therefore, it can be determined that phage GEP101 uses the E. coli lipopolysaccharide core polysaccharide as a target receptor.

[0066] Example 4

[0067] Determination of optimal phage infection multiplicity (MOI)

[0068] The multiplicity of infection (MOI) is the ratio of the number of phages to the number of bacteria during infection, and the optimal MOI is the ratio when the phage reaches the optimal growth condition.

[0069] Take the bacteriophage GEP101 (titer 10) stored at 4°C 8 PFU / mL), and Escherichia coli ATCC 35150 (10 7 CFU / mL), the bacterial solution and phage were oscillated and mixed at different infection ratios (respectively 100, 10, 1, 0.1, 0.01, 0.001, 0.0001), and cultured at 37°C and 160rpm for 4 hours. The mixture was centrifuged at 4°C and 12000×g for 2 minutes. The supernatant was immediately aspirated for 10-fold gradient dilution. The phage titer at different infection ratios was determined by the double-layer plate method. The multiplicity of infection at the highest phage titer was the optimal multiplicity of infection (MOI). The results are shown in Figure 4 As shown, the optimal MOI is 1 and the titer is 7×10 8 PFU / mL.

[0070] Example 5

[0071] One-step growth curve assay of phage

[0072] Phage GEP101 and Escherichia coli ATCC 35150 were mixed at an optimal infection multiplicity of 1, incubated at 37°C for 10 minutes, centrifuged at 12000×g for 30 seconds, the supernatant was removed, and the precipitate was resuspended and washed three times with LB liquid medium to remove the unadsorbed phages. The precipitate was resuspended with LB liquid medium, and the resuspended liquid was transferred to 30 mL LB liquid culture at 37°C, and immediately placed in 37°C, 160rpm shaking culture, and a sample was taken every 10 minutes. After 150 minutes, the sample was centrifuged at 10000×g for 2 minutes, and the supernatant was immediately aspirated for 10-fold gradient dilution. The phage titer at this time was determined by the double-layer plate method. Repeat three times. A one-step growth curve was drawn with the horizontal axis as the infection time and the vertical axis as the phage titer. The burst size of the phage is the ratio of the final number of free phage particles to the initial number of infected bacterial cells.

[0073] Results from Figure 5 As shown, the incubation period of bacteriophage GEP101 is 10 min, the burst period is 90 min, and the burst volume is 61 PFU / infected cell, indicating that the phage has the characteristics of a short incubation period and a large burst volume.

[0074] Example 6

[0075] pH stability assay of bacteriophage GEP101

[0076] The pH value of the buffer was adjusted using 1M HCl solution and 1M NaOH solution to prepare 11 buffers with different pH gradients (2-12). 8 PFU / mL) were mixed with buffers of different pH values, placed in a 37°C water bath for 60 min, and then diluted 10-fold with SM buffer, and the phage titers at different pH values ​​were determined by double-layer plate method. The above operation was repeated three times.

[0077] Results from Figure 6 It can be seen that the activity of the phage is stable in the pH range of 3-10, and it is inactivated at pH 11.

[0078] Example 7

[0079] Temperature stability assay of bacteriophage GEP101

[0080] 1 mL of phage GEP101 lysis buffer (10 8 The lysates were treated at 25, 37, 40, 50, 60 and 70 °C in a water bath for 80 min, and then the lysates treated at different temperatures were diluted 10-fold in a gradient manner. The phage titers at different temperatures were determined by the double-layer plate method, with three parallel groups set for each temperature.

[0081] Results from Figure 7 It can be seen that the activity of bacteriophage GEP101 is stable at 25-50℃, its activity is reduced to a certain extent at 60-70℃, and it is completely inactivated at 80℃.

[0082] Example 8

[0083] Phage GEP101 lysis curve assay

[0084] The overnight culture of E. coli ATCC 35150 was adjusted to about 10 7 CFU / mL, the experimental groups were added with different dilutions of phage GEP101 (titer of about 10 8 PFU / mL) was mixed with the bacterial solution and placed in a 37°C incubator for culture. A control group was set up, with only bacterial solution added without phage and only phage added without bacterial solution. The OD was measured every 30 minutes. 600nm The values ​​were measured for 12 h and the OD values ​​after adding phage were compared. 600nm Value changes.

[0085] Results from Figure 8 It can be seen that after adding different concentrations of phage, compared with the control group, all showed certain lytic activity, but after 8 hours, the OD 600nm The value increased to a certain extent, indicating that the host bacteria were not completely eliminated, resulting in an increase in the amount of bacteria. The lysis ability of phages at different concentrations on E. coli ATCC 35150 was different. When the phage concentration was high, it had a better inhibitory effect on E. coli ATCC 35150. Therefore, this provides an experimental basis for the future application of phages.

[0086] Example 9

[0087] Analysis of bacteriophage GEP101 genome

[0088] The phage GEP101 genome that met the sequencing requirements was submitted to a biological company for sequencing. Sequencing was performed using the IlluminaNovaSeq platform, and the sequencing data was spliced ​​using A5-MiSeq and SPAdes. The whole genome sequence has been submitted to GenBank, and the gene accession number is: PQ036202. The nucleotide sequence of the CEP101 gene was aligned on NCBI, and the genome was annotated using the RAST online website (http: / / rast.nmpdr.org / ), and then verified using the BLST tool of NCBI (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi). The CARD (https: / / card.mcmaster.ca / analyze / rgi) online website was used to analyze whether there were antibiotic resistance and virulence genes in the phage GEP101 genome, and finally the lysogeny-related proteins in the phage GEP101 genome were detected.

[0089] The results are as follows Fig. 9 Genome annotation: The full length of the phage GEP101 genome is 88,372bp. No antibiotic resistance and virulence genes were found in the phage genome, and there were no lysogeny-related genes.

[0090] Example 10

[0091] Antibacterial effect of bacteriophage GEP101 on enterohemorrhagic Escherichia coli O157:H7 in whole-fat sterilized milk at different MOI values ​​at 4℃ and 25℃

[0092] E. coli ATCC 35150 was cultured to the logarithmic growth phase, then washed three times with PBS and the precipitate was retained. The bacterial solution concentration was adjusted to 10 4 CFU / mL, set up control group and experimental group, the experimental group was set at MOI=100, 1000, 10000 (titer is 10 6 PFU / mL, 10 7 PFU / mL, 10 8 PFU / mL) was added with bacteriophage GEP101, and only an equal volume of PBS was added to the control group. The cells were cultured at 4°C and 25°C, respectively. Samples were taken at 3h, 6h, 9h, and 12h, and a 10-fold gradient dilution was performed. The plate count method was used to detect the number of Escherichia coli ATCC 35150 in milk, and the antibacterial effect of the phage was calculated.

[0093] Depend on Fig.10As shown in A, at 4°C, the number of bacteria in milk samples treated with bacteriophage GEP101 at MOI = 100, MOI = 1000 and MOI = 10000 decreased by 0.85 Log compared with the control group after 9 hours. 10 (CFU / mL), 1.12Log 10 (CFU / mL) and 1.21Log 10 (CFU / mL), indicating that bacteriophage GEP101 can play a good antibacterial effect at 4°C.

[0094] Depend on Fig.10 As shown in B, the milk sample treated with phage at MOI = 100 at 25 ° C for 9 hours reduced the 1.25Log 10 (CFU / mL); After 9 hours of treatment with phages at MOI = 1000, the number of bacteria in milk samples decreased by 1.75 Log compared with the control group 10 (CFU / mL); 25℃, MOI=10000 phage treated milk sample 9h after bacterial count decreased by 1.89Log compared with the control group 10 (CFU / mL), indicating that bacteriophage GEP101 can play a good antibacterial effect at 25℃.

[0095] Example 10 The bacteriophage antibacterial experiment on milk proves that the bacteriophage has a good inhibitory effect on Escherichia coli ATCC35150 in food.

[0096] It can be seen from the above examples that the E. coli phage of the present invention can lyse E. coli of different serotypes, effectively inhibit E. coli and prevent E. coli infection.

[0097] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. An Escherichia coliphage GEP101, wherein the deposit number of the Escherichia coli phage GEP101 is CCTCC NO: M 20241332.

2. Use of the Escherichia coli phage GEP101 according to claim 1 in the preparation of a preparation for inhibiting and / or lysing Escherichia coli.

3. The use according to claim 2, characterized in that: The formulations include formulations that target the Escherichia coli lipopolysaccharide core polysaccharide.

4. The use according to claim 2 or 3, characterized in that: The Escherichia coli includes one or more of serotype Escherichia coli O157, serotype Escherichia coli O66, serotype Escherichia coli O77 / O17, serotype Escherichia coli K88, serotype Escherichia coli O131, serotype Escherichia coli O177 and serotype Escherichia coli O159.

5. The use according to claim 2, characterized in that: The infection multiplicity of the Escherichia coli phage GEP101 is 0.01-10.

6. The use according to claim 2, characterized in that: The preparation includes a food antibacterial agent.

7. The use according to claim 6, characterized in that: The food comprises food of animal origin.

8. The use according to claim 2, characterized in that: The preparation comprises a drug for preventing and / or treating diseases caused by Escherichia coli infection.

9. A preparation for inhibiting and / or lysing Escherichia coli, characterized in that: The invention comprises the Escherichia coli phage GEP101 as claimed in claim 1 and auxiliary materials.

10. The preparation according to claim 9, characterized in that The content of Escherichia coli phage GEP101 added to the preparation is 10 6 PFU / mL~10 8 PFU / mL.

Citation Information

Patent Citations

  • Novel enterohemorrhagic e. coli bacteriophage esc-chp-1 and use thereof for inhibiting proliferation of enterohemorrhagic e. coli

    CN107257853A

  • Wide-lysis-spectrum Escherichia coli phage and composition, kit and application thereof

    CN110846283A

  • Broad-spectrum escherichia coli phage, composition and kit capable of simultaneously cracking four bacteria, and application of broad-spectrum escherichia coli phage

    CN112680423A

  • Escherichia coli phage GN4-1 and application thereof

    CN113755450A

  • Phage STP55 capable of simultaneously cracking salmonella and escherichia coli and application

    CN114703148A